Press Releases
Samsung Biologics, PharmAbcine Enter Antibody Pact
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacture of PMC-402 pipeline, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders.
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacture of PMC-402 pipeline, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders.